Arrowhead Pharmaceuticals and Sarepta Therapeutics have formed a partnership to develop treatments for rare genetic diseases. The deal includes a substantial upfront payment, equity investment, and potential milestone payments. The collaboration targets rare diseases affecting muscles, lungs, and the central nervous system.